What is the history of Congenital Adrenal Hyperplasia (CAH)?

Congenital Adrenal Hyperplasia (CAH) was first clinically described in 1865 by Luigi De Crecchio, who identified the condition during a post-mortem examination of a person with ambiguous genitalia. Since then, understanding of Congenital Adrenal Hyperplasia (CAH) has evolved from a mysterious anatomical anomaly to a well-defined group of autosomal recessive genetic disorders involving enzymatic deficiencies in cortisol biosynthesis.

When was Congenital Adrenal Hyperplasia (CAH) first identified?

The history of Congenital Adrenal Hyperplasia (CAH) dates back to the 19th century. After De Crecchio’s initial 1865 report, the condition was often referred to as the "adrenogenital syndrome." For decades, physicians struggled to explain the connection between adrenal gland enlargement and altered sexual development, often misinterpreting the physical signs as separate hormonal tumors.

How has our understanding of Congenital Adrenal Hyperplasia (CAH) evolved?

The mid-20th century marked a revolutionary shift. In 1950, Lawson Wilkins discovered that treating Congenital Adrenal Hyperplasia (CAH) with cortisone could suppress the overproduction of adrenal androgens. This was a landmark moment, as it shifted the condition from a life-threatening crisis in infancy to a manageable chronic endocrine disorder. By the 1970s and 1980s, the development of molecular genetics allowed researchers to map the CYP21A2 gene, which is responsible for over 90% of cases.

What are the major milestones in managing the disease?

The management of Congenital Adrenal Hyperplasia (CAH) has seen several critical advancements:

• 1950: First successful use of cortisone therapy to manage adrenal suppression.


• 1970s: Implementation of prenatal screening and diagnostic protocols.


• 1980s: Identification of the CYP21A2 gene on chromosome 6p21.3.


• Modern Era: Introduction of newborn screening programs in many countries to prevent salt-wasting crises.

How has patient advocacy changed the landscape?

Historically, the medical focus on Congenital Adrenal Hyperplasia (CAH) was strictly clinical. Today, the focus has shifted toward quality of life. With 81 community members currently sharing their experiences on DiseaseMaps.org, patients now lead the conversation regarding long-term fertility, psychological health, and the ethics of early surgical interventions, ensuring that the modern treatment of Congenital Adrenal Hyperplasia (CAH) remains patient-centered.

Next steps

• Consult a pediatric endocrinologist to ensure your management plan is based on the latest clinical guidelines.


• Join the DiseaseMaps community to connect with others sharing their journey with this condition.


• Stay informed by reviewing updates from the CARES Foundation or NIH GARD.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician regarding any medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Congenital Adrenal Hyperplasia.


• Orphanet: Congenital Adrenal Hyperplasia (ORPHA:198).


• OMIM (Online Mendelian Inheritance in Man): 21-Hydroxylase Deficiency (#201910).


• The CARES Foundation (Congenital Adrenal Hyperplasia research and support).